INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241401, 'Colistimethate', 'Chlorambucil', 'Moderate', 'The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.', 'DDInter', 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267425/', '', 'Temozolomide, Thiotepa, Carmustine, Busulfan, Streptozocin, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Melphalan flufenamide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241402, 'Ibritumomab tiuxetan', 'Chlorambucil', 'Moderate', 'The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.', 'DDInter', 'Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers'' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.', 'Synergism', 'Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267432/', '', 'Uracil mustard', 'Tositumomab, Iodide I-131', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241403, 'Chlorambucil', 'Melphalan flufenamide', 'Moderate', 'The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.', 'DDInter', 'Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers'' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.', 'Synergism', 'Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267441/', '', 'Melphalan, Melphalan flufenamide, Uracil mustard', 'Chlorambucil, Uracil mustard', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241404, 'Chlorambucil', 'Polymyxin B', 'Moderate', 'The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.', 'DDInter', 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267451/', '', 'Temozolomide, Thiotepa, Carmustine, Busulfan, Streptozocin, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Melphalan flufenamide', 'Tetracycline, Rifamycin, Miconazole, Gentamicin, Chlorhexidine, Neomycin, Tetracycline, Chlorhexidine, Neomycin, Gentamicin, Tinidazole, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241405, 'Chlorambucil', 'Telavancin', 'Moderate', 'The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.', 'DDInter', 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267474/', '', 'Temozolomide, Thiotepa, Carmustine, Busulfan, Streptozocin, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Melphalan flufenamide', 'Tinidazole, Linezolid, Oritavancin, Daptomycin, Metronidazole, Methenamine, Spectinomycin, Lefamulin, Nitrofurantoin, Fosfomycin, Tedizolid, Dalbavancin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241406, 'Chlorambucil', 'Vancomycin', 'Moderate', 'The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.', 'DDInter', 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267478/', '', 'Lomustine, Mechlorethamine, Bendamustine, Melphalan flufenamide, Streptozocin', 'Tinidazole, Linezolid, Oritavancin, Daptomycin, Metronidazole, Methenamine, Spectinomycin, Lefamulin, Nitrofurantoin, Fosfomycin, Tedizolid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241407, 'Chlorambucil', 'Varicella Zoster Vaccine (Recombinant)', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.', 'DDInter', 'In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual''s risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'In general, the U.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267481/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241408, 'Chloramphenicol', 'Bevacizumab', 'Moderate', 'Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of chloramphenicol hematologic toxicity.', 'DDInter', 'Concurrent use of chloramphenicol with other bone marrow depressing agents should be avoided.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267483/', '', 'Pertuzumab, Cetuximab, Olaratumab, Avelumab, Panitumumab, Necitumumab, Dostarlimab, Amivantamab, Ramucirumab, Atezolizumab, Nivolumab, More', 'Tetracycline, Mupirocin, Rifamycin, Oxytetracycline, Bacitracin, Demeclocycline, Rifaximin, Gentamicin, Amikacin, Neomycin, Tetracycline, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241409, 'Drospirenone', 'Chloramphenicol', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of drospirenone, which is partially metabolized by the isoenzyme.', 'DDInter', 'Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.g., renal insufficiency; coadministration with medications that can increase potassium such as aldosterone antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium-sparing diuretics, potassium supplements, and heparin).  Consider checking serum potassium levels during the first treatment cycle and periodically thereafter as indicated.', 'Metabolism', 'Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267486/', '', 'Tetracycline, Mupirocin, Rifamycin, Oxytetracycline, Bacitracin, Demeclocycline, Rifaximin, Gentamicin, Amikacin, Neomycin, Tetracycline, More', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Etynodiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, Dienogest, Estetrol, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241410, 'Imatinib', 'Chloramphenicol', 'Moderate', 'Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of chloramphenicol hematologic toxicity.', 'DDInter', 'Concurrent use of chloramphenicol with other bone marrow depressing agents should be avoided.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267493/', '', 'Tetracycline, Mupirocin, Rifamycin, Oxytetracycline, Bacitracin, Demeclocycline, Rifaximin, Gentamicin, Amikacin, Neomycin, Tetracycline, More', 'Dabrafenib, Dacomitinib, Vemurafenib, Vandetanib, Afatinib, Tivozanib, Sunitinib, Regorafenib, Alpelisib, Lenvatinib, Erlotinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241411, 'Chloramphenicol', 'Melphalan flufenamide', 'Moderate', 'Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of chloramphenicol hematologic toxicity.', 'DDInter', 'Concurrent use of chloramphenicol with other bone marrow depressing agents should be avoided.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267501/', '', 'Tetracycline, Mupirocin, Rifamycin, Oxytetracycline, Bacitracin, Demeclocycline, Rifaximin, Gentamicin, Amikacin, Neomycin, Tetracycline, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241412, 'Chloramphenicol', 'Promazine', 'Moderate', 'Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of chloramphenicol hematologic toxicity.', 'DDInter', 'Concurrent use of chloramphenicol with other bone marrow depressing agents should be avoided.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267511/', '', 'Tetracycline, Mupirocin, Rifamycin, Oxytetracycline, Bacitracin, Demeclocycline, Rifaximin, Gentamicin, Amikacin, Neomycin, Tetracycline, More', 'Fluphenazine, Haloperidol, Thiothixene, Risperidone, Amisulpride, Prochlorperazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, Mesoridazine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241413, 'Chloramphenicol', 'Tramadol', 'Moderate', 'Coadministration with drugs that are inhibitors of the CYP450 3A4 isoenzymes may increase the plasma concentrations of tramadol and its active O-demethylated metabolite.', 'DDInter', 'Caution is advised if tramadol is used concomitantly with medications that inhibit CYP450 3A4 metabolism.  Dosage adjustments as well as clinical monitoring may be appropriate whenever there drugs are added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if tramadol is used concomitantly with medications that inhibit CYP450 3A4 metabolism.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267515/', '', 'Mupirocin, Rifamycin, Oxytetracycline, Bacitracin, Demeclocycline, Rifaximin, Gentamicin, Amikacin, Neomycin, Rifamycin, Polymyxin B, More', 'Codeine, Morphine, Naltrexone, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Dezocine, Opium, Dextropropoxyphene, Celecoxib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241414, 'Chlordiazepoxide', 'Acrivastine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267519/', '', 'Ketotifen, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241415, 'Chlordiazepoxide', 'Chlorcyclizine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267522/', '', 'Ketotifen, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine', 'Meprobamate, Oxazepam', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241416, 'Dimenhydrinate', 'Chlordiazepoxide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267527/', '', 'Ketotifen, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241417, 'Fenfluramine', 'Chlordiazepoxide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267529/', '', 'Dexfenfluramine, Naltrexone, Ephedrine, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241418, 'Chlordiazepoxide', 'Methotrimeprazine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267533/', '', 'Meprobamate, Alprazolam, Lorazepam, Halazepam, Buspirone, Diazepam, Oxazepam', 'Amisulpride, Pimavanserin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241419, 'Chlordiazepoxide', 'Selegiline', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267536/', '', 'Amantadine, Cabergoline', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241420, 'Chlordiazepoxide', 'Thiopental', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267539/', '', 'Meprobamate, Diazepam, Lorazepam, Buspirone, Hydroxyzine, Oxazepam', 'Etomidate, Nitrous oxide, Nitrazepam, Zopiclone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241421, 'Elvitegravir', 'Magnesium chloride', 'Moderate', 'The concomitant use of antacids or oral products containing polyvalent cations (e.g., Mg, Al, Ca, Fe, Zn) may significantly decrease the plasma concentrations of elvitegravir.  According to the elvitegravir manufacturer, the mechanism of the interaction may be related to local complexation in the gastrointestinal tract and not to changes in gastric pH.', 'DDInter', 'Antacid and oral products containing polyvalent cations should be administered at least 2 hours before or 2 hours after the elvitegravir dose.  Some experts recommend an interval of at least 4 hours.  Alternatively, H2-receptor antagonists or proton pump inhibitors may be considered instead of antacids, with no dosage adjustment needed.', 'Absorption', 'Antacid and oral products containing polyvalent cations should be administered at least 2 hours before or 2 hours after the elvitegravir dose.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267540/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More', 'Sodium chloride, Sodium sulfate, Calcium chloride, Potassium chloride, Sodium acetate, Arginine, Sodium glycerophosphate, Tromethamine, Sodium phosphate, monobasic, Sodium chloride, Potassium acetate, Ammonium chloride', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241422, 'Cyclophosphamide', 'Chloroprocaine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', 'DDInter', 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267549/', '', 'Temozolomide, Thiotepa, Carmustine, Busulfan, Streptozocin, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Melphalan, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241423, 'Dapsone', 'Chloroprocaine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', 'DDInter', 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267550/', '', 'Meloxicam', 'Minocycline, Clindamycin, Vitamin A, Isotretinoin, Dexamethasone, Chloramphenicol, Fluorometholone, Tretinoin, Erythromycin, Methylprednisolone, Azelaic acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241424, 'Flutamide', 'Chloroprocaine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', 'DDInter', 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267551/', '', 'Meloxicam', 'Darolutamide, Tamoxifen, Anastrozole, Aminoglutethimide, Letrozole, Toremifene, Fulvestrant, Abarelix, Enzalutamide, Relugolix, Bicalutamide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241425, 'Hydroxyurea', 'Chloroprocaine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', 'DDInter', 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267552/', '', 'Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241426, 'Ifosfamide', 'Chloroprocaine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', 'DDInter', 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267553/', '', 'Etidocaine, Levobupivacaine, Meloxicam', 'Temozolomide, Thiotepa, Carmustine, Busulfan, Streptozocin, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Melphalan, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241427, 'Isosorbide', 'Chloroprocaine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', 'DDInter', 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267554/', '', 'Etidocaine, Levobupivacaine, Meloxicam', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241428, 'Isosorbide mononitrate', 'Chloroprocaine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', 'DDInter', 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267555/', '', 'Nesiritide, Vericiguat', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241429, 'Chloroprocaine', 'Metoclopramide', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', 'DDInter', 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267556/', '', 'Cisapride', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241430, 'Chloroprocaine', 'Nitric Oxide', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', 'DDInter', 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267557/', '', 'Etidocaine, Levobupivacaine, Meloxicam', 'Doxapram, Ivacaftor, Elexacaftor, Lumacaftor', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241431, 'Chloroprocaine', 'Nitrofurantoin', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', 'DDInter', 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267558/', '', 'Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241432, 'Chloroprocaine', 'Nitroglycerin', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', 'DDInter', 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267559/', '', 'Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Diltiazem, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241433, 'Chloroprocaine', 'Nitrous oxide', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', 'DDInter', 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267560/', '', 'Meloxicam', 'Halothane, Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Fentanyl, Desflurane, Sufentanil, Propofol, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241434, 'Chloroprocaine', 'Phenytoin', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', 'DDInter', 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267561/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241435, 'Chloroprocaine', 'Primaquine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', 'DDInter', 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267562/', '', 'Meloxicam', 'Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Atovaquone, Hydroxychloroquine, Halofantrine, Proguanil', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241436, 'Chloroprocaine', 'Quinine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', 'DDInter', 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267564/', '', 'Meloxicam', 'Risdiplam, Collagenase clostridium histolyticum, Onasemnogene abeparvovec, Hyaluronic acid, Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Atovaquone, Hydroxychloroquine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241437, 'Chloroprocaine', 'Rasburicase', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', 'DDInter', 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267565/', '', 'Etidocaine, Levobupivacaine, Meloxicam', 'Hydroxocobalamin, Fomepizole, Ipecac, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, Promethazine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241438, 'Chloroprocaine', 'Silver nitrate (topical)', 'Moderate', 'Topical nitrate and silver (e.g., cerium nitrate, silver nitrate, silver sulfadiazine) preparations can be systemically absorbed and have been associated with rare reports of methemoglobinemia, primarily in burn patients.  In addition, bacterial conversion of nitrate to nitrite can contribute to methemoglobinemia.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as ester and amide local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), systemic nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', 'DDInter', 'Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when treating burn patients.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267566/', '', 'Etidocaine, Levobupivacaine, Meloxicam', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241439, 'Chloroprocaine', 'Silver sulfadiazine (topical)', 'Moderate', 'Topical nitrate and silver (e.g., cerium nitrate, silver nitrate, silver sulfadiazine) preparations can be systemically absorbed and have been associated with rare reports of methemoglobinemia, primarily in burn patients.  In addition, bacterial conversion of nitrate to nitrite can contribute to methemoglobinemia.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as ester and amide local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), systemic nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', 'DDInter', 'Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when treating burn patients.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267567/', '', 'Etidocaine, Levobupivacaine, Meloxicam', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241440, 'Chloroprocaine', 'Sulfamethizole', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', 'DDInter', 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267568/', '', 'Etidocaine, Levobupivacaine, Meloxicam', 'Sorbitol, Sodium citrate, Magnesium citrate, Mannitol, Sodium bicarbonate, Sodium chloride, Chlorhexidine, Neomycin, Tamsulosin, Tinidazole, Ascorbic acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241441, 'Chloroprocaine', 'Sulfisoxazole', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', 'DDInter', 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267569/', '', 'Meloxicam', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Methazolamide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241442, 'Chloroprocaine', 'Tafenoquine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', 'DDInter', 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267570/', '', 'Etidocaine, Levobupivacaine, Meloxicam', 'Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Atovaquone, Hydroxychloroquine, Halofantrine, Proguanil', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241443, 'Dexmethylphenidate', 'Chlorothiazide', 'Moderate', 'Methylphenidate and other derivative amphetamines may decrease the therapeutic effects of antihypertensive drugs.', 'DDInter', 'Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.  The dosage of the antihypertensive drug should be adjusted as needed.', 'Antagonism', 'Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267575/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More', 'Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dextroamphetamine, Armodafinil, Citicoline, Modafinil', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241444, 'Darolutamide', 'Chlorpromazine', 'Moderate', 'Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.', 'Synergism', 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267595/', '', 'Haloperidol, Thiothixene, Amisulpride, Promazine, Thioridazine, Lumateperone, Pimozide, Cariprazine, Mesoridazine, Pimavanserin, Clozapine, More', 'Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241445, 'Fenfluramine', 'Chlorpromazine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267602/', '', 'Amisulpride, Pimavanserin', 'Dexfenfluramine, Naltrexone, Lacosamide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241446, 'Chlorpromazine', 'Melatonin', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267610/', '', 'Amisulpride, Pimavanserin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241447, 'Chlorpromazine', 'Botulinum toxin type A', 'Moderate', 'Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.', 'DDInter', 'Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.', 'Synergism', 'Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267615/', '', 'Quetiapine, Asenapine, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Risperidone, Amisulpride, Aripiprazole, Droperidol, Cariprazine, More', 'Atracurium, Doxacurium, Succinylcholine, Rocuronium, Vecuronium, Tubocurarine, Mivacurium, Pancuronium, Pipecuronium, Cisatracurium', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241448, 'Chlorpromazine', 'Pralsetinib', 'Moderate', 'Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267618/', '', 'Amisulpride, Loxapine, Molindone, Thiothixene', 'Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Cobimetinib, Ibrutinib, Afatinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241449, 'Chlorpromazine', 'Botulinum toxin type B', 'Moderate', 'Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.', 'DDInter', 'Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.', 'Synergism', 'Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267620/', '', 'Quetiapine, Asenapine, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Risperidone, Amisulpride, Aripiprazole, Droperidol, Cariprazine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241450, 'Chlorthalidone', 'Butalbital', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267628/', '', 'Suvorexant, Nitrazepam, Thiopental, Eszopiclone, Ramelteon, Lemborexant, Methohexital, Estazolam, Tasimelteon, Melatonin, Primidone, Valerian', 'Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241451, 'Chlorthalidone', 'Chlormezanone', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267631/', '', 'Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241452, 'Dexmethylphenidate', 'Chlorthalidone', 'Moderate', 'Methylphenidate and other derivative amphetamines may decrease the therapeutic effects of antihypertensive drugs.', 'DDInter', 'Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.  The dosage of the antihypertensive drug should be adjusted as needed.', 'Antagonism', 'Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267633/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More', 'Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dextroamphetamine, Armodafinil, Citicoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241453, 'Dezocine', 'Chlorthalidone', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267634/', '', 'Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More', 'Naloxone, Naltrexone, Tapentadol', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241454, 'Ethchlorvynol', 'Chlorthalidone', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267636/', '', 'Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More', 'Suvorexant, Nitrazepam, Thiopental, Eszopiclone, Ramelteon, Lemborexant, Methohexital, Estazolam, Tasimelteon, Melatonin, Primidone, Valerian', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241455, 'Halazepam', 'Chlorthalidone', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267639/', '', 'Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241456, 'Chlorthalidone', 'Levorphanol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267643/', '', 'Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241457, 'Chlorthalidone', 'Methylphenobarbital', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267644/', '', 'Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More', 'Brivaracetam, Ezogabine, Cenobamate, Lamotrigine, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241458, 'Chlorthalidone', 'Metaxalone', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267645/', '', 'Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241459, 'Chlorthalidone', 'Oxymorphone', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267648/', '', 'Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More', 'Naloxone, Naltrexone, Tapentadol', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241460, 'Chlorthalidone', 'Pentobarbital', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267649/', '', 'Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More', 'Suvorexant, Nitrazepam, Thiopental, Eszopiclone, Ramelteon, Lemborexant, Methohexital, Estazolam, Tasimelteon, Melatonin, Primidone, Valerian', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241461, 'Chlorthalidone', 'Quazepam', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267650/', '', 'Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, More', 'Suvorexant, Nitrazepam, Thiopental, Eszopiclone, Ramelteon, Lemborexant, Methohexital, Estazolam, Tasimelteon, Melatonin, Primidone, Valerian', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241462, 'Chlorzoxazone', 'Acrivastine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267656/', '', 'Methdilazine, Ketotifen, Chlorcyclizine, Fexofenadine, Thiethylperazine, Phenindamine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241463, 'Dantrolene', 'Chlorzoxazone', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267659/', '', 'Cyclobenzaprine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241464, 'Dimenhydrinate', 'Chlorzoxazone', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267663/', '', 'Methdilazine, Ketotifen, Chlorcyclizine, Fexofenadine, Thiethylperazine, Phenindamine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241465, 'Fenfluramine', 'Chlorzoxazone', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267664/', '', 'Tizanidine', 'Dexfenfluramine, Ephedrine, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241466, 'Chlorzoxazone', 'Levodopa', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267667/', '', 'Amantadine, Cabergoline', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241467, 'Chlorzoxazone', 'Melatonin', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267669/', '', 'Tizanidine', 'Ethchlorvynol, Zopiclone, Dichloralphenazone, Nitrazepam', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241468, 'Chlorzoxazone', 'Botulinum toxin type A', 'Moderate', 'Excessive muscle weakness associated with the use of botulism toxin may be exaggerated by concomitant use of a skeletal muscle relaxant.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings and is a neuromuscular blocking agent, thus additive effects may occur with muscle relaxants.', 'DDInter', 'Patients should be advised that muscle weakness may be increased when botulinum toxin is used in combination with skeletal muscle relaxants.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267671/', '', 'Chlormezanone', 'Atracurium, Doxacurium, Succinylcholine, Rocuronium, Vecuronium, Tubocurarine, Mivacurium, Pancuronium, Pipecuronium, Cisatracurium', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241469, 'Chlorzoxazone', 'Botulinum toxin type B', 'Moderate', 'Excessive muscle weakness associated with the use of botulism toxin may be exaggerated by concomitant use of a skeletal muscle relaxant.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings and is a neuromuscular blocking agent, thus additive effects may occur with muscle relaxants.', 'DDInter', 'Patients should be advised that muscle weakness may be increased when botulinum toxin is used in combination with skeletal muscle relaxants.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267673/', '', 'Chlormezanone', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241470, 'Chlorzoxazone', 'Selegiline', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267674/', '', 'Tizanidine', 'Amantadine, Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241471, 'Vibrio cholerae CVD 103-HgR strain live antigen (live)', 'Melphalan flufenamide', 'Moderate', 'There are no data regarding the use of live, attenuated cholera vaccine during treatment with immunosuppressive therapies, including alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.  It is not known whether immunosuppressed patients may have an increased risk of adverse reactions or a decreased or suboptimal immunologic response to the vaccine.', 'DDInter', 'The safety and efficacy of live, attenuated cholera vaccine have not been established in patients receiving immunosuppressive therapies.  Caution is advised.', 'Others', 'The safety and efficacy of live, attenuated cholera vaccine have not been established in patients receiving immunosuppressive therapies.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267688/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241472, 'Cidofovir', 'Moxetumomab Pasudotox', 'Major', 'Coadministration of cidofovir with other nephrotoxic agents may increase the risk of renal impairment due to additive effects on the kidney.  Dose-related nephrotoxicity is the major toxicity of cidofovir.', 'DDInter', 'Concomitant use of cidofovir with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; aminosalicylates; antiviral/antiretroviral agents such as acyclovir, adefovir, foscarnet, ganciclovir, and tenofovir; antineoplastics such as aldesleukin, cisplatin, clofarabine, ifosfamide, streptozocin, and high intravenous dosages of methotrexate; chelating agents such as deferasirox, deferoxamine, edetate disodium, and edetate calcium disodium; immunosuppressants such as cyclosporine, everolimus, sirolimus, and tacrolimus; intravascular contrast media; intravenous bisphosphonates; intravenous pentamidine; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents; gallium nitrate; lithium; penicillamine) is considered contraindicated.  Such agents should be discontinued for at least seven days prior to starting therapy with cidofovir.  Initiation of cidofovir is also contraindicated in patients with a serum creatinine >1.5 mg/dL, a calculated creatinine clearance <=55 mL/min, or a urine protein >=100 mg/dL (2+ proteinuria or greater).', 'Synergism', 'Concomitant use of cidofovir with other potentially nephrotoxic agents (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267732/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241473, 'Darolutamide', 'Cilostazol', 'Moderate', 'Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.', 'Synergism', 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267739/', '', 'Ticagrelor, Betrixaban, Clopidogrel, Apixaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Warfarin, More', 'Anastrozole, Aminoglutethimide, Exemestane, Fulvestrant', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241474, 'Heparin (flush)', 'Cilostazol', 'Moderate', 'Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.', 'DDInter', 'Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.', 'Synergism', 'Caution and monitoring (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267743/', '', 'Acenocoumarol, Selexipag', 'Cilostazol, Dicoumarol, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Ascorbic acid, Vitamin A, Potassium Iodide, Acetylcysteine, Nandrolone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241475, 'Cilostazol', 'Pralsetinib', 'Moderate', 'Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267754/', '', 'Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, Argatroban, Prasugrel, Desirudin, Eptifibatide, More', 'Dacomitinib, Pexidartinib, Tepotinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, Axitinib, Ripretinib, Alpelisib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241476, 'Drospirenone', 'Cimetidine', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of drospirenone, which is partially metabolized by the isoenzyme.', 'DDInter', 'Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.g., renal insufficiency; coadministration with medications that can increase potassium such as aldosterone antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium-sparing diuretics, potassium supplements, and heparin).  Consider checking serum potassium levels during the first treatment cycle and periodically thereafter as indicated.', 'Metabolism', 'Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267764/', '', 'Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Estetrol, Etonogestrel, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241477, 'Denosumab', 'Cinacalcet', 'Moderate', 'Coadministration of denosumab with calcimimetic drugs such as cinacalcet and etelcalcetide, may increase the risk of hypocalcemia.  This risk may be significantly higher in patients with severe renal dysfunction (creatinine clearance less than 30 mL/min) and in those receiving dialysis.  The mechanism of this interaction is thought to be due to additive hypocalcemic effects.', 'DDInter', 'Caution and close monitoring of serum calcium concentrations are recommended when denosumab is used concomitantly with calcimimetic drugs such as cinacalcet and etelcalcetide.  Patients and clinicians should be alert for signs and symptoms of hypocalcemia, such as numbness or tingling in the fingers, toes, or around the mouth, muscle spasms, twitches or cramps, seizures, mental status changes (confusion, irritability, depression), and irregular heartbeats.', 'Synergism', 'Caution and close monitoring of serum calcium concentrations are recommended when denosumab is used concomitantly with calcimimetic drugs such as cinacalcet and etelcalcetide.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267782/', '', 'Paricalcitol, Doxercalciferol, Salmon calcitonin, Calcifediol', 'Tiludronic acid, Vosoritide, Etidronic acid, Ibandronate, Cholecalciferol, Romosozumab, Pamidronic acid', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241478, 'Enzalutamide', 'Cinacalcet', 'Moderate', 'Coadministration with enzalutamide may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, 2C9, 2C19, and/or P-glycoprotein (P-gp) efflux transporter.  The proposed mechanism involves accelerated clearance via these routes due to enzalutamide-mediated induction.', 'DDInter', 'Caution is advised when enzalutamide is used concomitantly with drugs that are substrates of CYP450 3A4, 2C9, 2C19, and/or P-gp, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever enzalutamide is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when enzalutamide is used concomitantly with drugs that are substrates of CYP450 3A4, 2C9, 2C19, and/or P-gp, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267783/', '', 'Etelcalcetide, Doxercalciferol, Salmon calcitonin, Calcifediol', 'Darolutamide, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241479, 'Cinacalcet', 'Osilodrostat', 'Moderate', 'Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.', 'DDInter', 'Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267787/', '', 'Etelcalcetide, Doxercalciferol, Salmon calcitonin, Calcifediol, Paricalcitol', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241480, 'Cinacalcet', 'Pralsetinib', 'Moderate', 'Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.', 'DDInter', 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.', 'Metabolism', 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267789/', '', 'Etelcalcetide, Salmon calcitonin, Calcifediol', 'Entrectinib, Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Vemurafenib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241481, 'Cinoxacin', 'Acetohexamide', 'Major', 'Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents.  The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin.', 'DDInter', 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.  Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides).  Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician.  Alternative antibiotics may need to be considered.', 'Others', 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267791/', '', 'Simvastatin, Guar gum, Rosuvastatin', 'Enoxacin, Lomefloxacin, Grepafloxacin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241482, 'Anisindione', 'Cinoxacin', 'Major', 'Some quinolone antibiotics have been reported to potentiate the hypoprothrombinemic effect of warfarin and other coumarin anticoagulants.  The exact mechanism is unknown but may involve inhibition of coumarin metabolism and/or depletion of certain clotting factors due to suppression of vitamin K-producing intestinal flora.', 'DDInter', 'Given the potential for clinically significant interaction and even fatality in the occasional, susceptible patient, close monitoring is recommended if a quinolone antibiotic is prescribed during coumarin anticoagulant therapy.  The INR should be checked frequently and coumarin dosage adjusted accordingly, particularly following initiation or discontinuation of quinolone therapy in patients who are stabilized on their anticoagulant regimen.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  The same precaution may be applicable during therapy with other oral anticoagulants (e.g., indandiones), although clinical data are lacking.', 'Synergism', 'Given the potential for clinically significant interaction and even fatality in the occasional, susceptible patient, close monitoring is recommended if a quinolone antibiotic is prescribed during coumarin anticoagulant therapy.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267793/', '', 'Enoxacin, Delafloxacin, Lomefloxacin, Grepafloxacin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241483, 'Cinoxacin', 'Attapulgite', 'Moderate', 'Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics.  Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc.  The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.  When coadministered with Suprep Bowel Prep (magnesium/potassium/sodium sulfates), the manufacturer recommends administering fluoroquinolone antibiotics at least 2 hours before and not less than 6 hours after Suprep Bowel Prep to avoid chelation with magnesium.  Please consult individual product labeling for specific recommendations.', 'Absorption', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267794/', '', 'Pectin, Activated charcoal', 'Enoxacin, Lomefloxacin, Grepafloxacin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241484, 'Cinoxacin', 'Axicabtagene ciloleucel', 'Minor', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.', 'DDInter', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.  In six patients with newly diagnosed hematologic malignancy, treatment with various antineoplastic agents (cyclophosphamide, cytarabine, daunorubicin, doxorubicin, mitoxantrone, prednisolone, vincristine) decreased the mean peak serum concentration (Cmax) and area under the concentration-time curve (AUC 0 to 4 hours) of ciprofloxacin by approximately 46% each.  Data are not available for other quinolone antibiotics.', 'Absorption', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267795/', '', 'Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Omacetaxine mepesuccinate, Tazemetostat, Tagraxofusp, Pegaspargase, Ixazomib, More', 'Enoxacin, Lomefloxacin, Grepafloxacin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241485, 'Cinoxacin', 'Bifidobacterium longum infantis', 'Moderate', 'Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic.  It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations.', 'DDInter', 'Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267796/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241486, 'Cinoxacin', 'Bromfenac', 'Moderate', 'Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use.  The interaction has been reported most often with enoxacin.  It may occur with other fluoroquinolones as well, but is poorly documented.  The exact mechanism of interaction is unknown.  Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect.  Patients with a history of seizures may be at greater risk.', 'DDInter', 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267797/', '', 'Fluocinolone acetonide, Fluorometholone', 'Enoxacin, Lomefloxacin, Grepafloxacin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241487, 'Cinoxacin', 'Calcium glycerophosphate', 'Moderate', 'Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics.  Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc.  The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.  When coadministered with Suprep Bowel Prep (magnesium/potassium/sodium sulfates), the manufacturer recommends administering fluoroquinolone antibiotics at least 2 hours before and not less than 6 hours after Suprep Bowel Prep to avoid chelation with magnesium.  Please consult individual product labeling for specific recommendations.', 'Absorption', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267798/', '', 'Enoxacin, Lomefloxacin, Grepafloxacin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241488, 'Copper gluconate', 'Cinoxacin', 'Moderate', 'Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics.  Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc.  The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.  When coadministered with Suprep Bowel Prep (magnesium/potassium/sodium sulfates), the manufacturer recommends administering fluoroquinolone antibiotics at least 2 hours before and not less than 6 hours after Suprep Bowel Prep to avoid chelation with magnesium.  Please consult individual product labeling for specific recommendations.', 'Absorption', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267800/', '', 'Enoxacin, Lomefloxacin, Grepafloxacin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241489, 'Dicoumarol', 'Cinoxacin', 'Major', 'Some quinolone antibiotics have been reported to potentiate the hypoprothrombinemic effect of warfarin and other coumarin anticoagulants.  The exact mechanism is unknown but may involve inhibition of coumarin metabolism and/or depletion of certain clotting factors due to suppression of vitamin K-producing intestinal flora.', 'DDInter', 'Given the potential for clinically significant interaction and even fatality in the occasional, susceptible patient, close monitoring is recommended if a quinolone antibiotic is prescribed during coumarin anticoagulant therapy.  The INR should be checked frequently and coumarin dosage adjusted accordingly, particularly following initiation or discontinuation of quinolone therapy in patients who are stabilized on their anticoagulant regimen.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  The same precaution may be applicable during therapy with other oral anticoagulants (e.g., indandiones), although clinical data are lacking.', 'Synergism', 'Given the potential for clinically significant interaction and even fatality in the occasional, susceptible patient, close monitoring is recommended if a quinolone antibiotic is prescribed during coumarin anticoagulant therapy.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267802/', '', 'Enoxacin, Delafloxacin, Lomefloxacin, Grepafloxacin', 'Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241490, 'Insulin human', 'Cinoxacin', 'Major', 'Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents.  The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin.', 'DDInter', 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.  Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides).  Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician.  Alternative antibiotics may need to be considered.', 'Others', 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267806/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241491, 'Insulin aspart (aspart protamine)', 'Cinoxacin', 'Major', 'Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents.  The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin.', 'DDInter', 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.  Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides).  Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician.  Alternative antibiotics may need to be considered.', 'Others', 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267807/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241492, 'Insulin lispro (protamine)', 'Cinoxacin', 'Major', 'Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents.  The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin.', 'DDInter', 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.  Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides).  Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician.  Alternative antibiotics may need to be considered.', 'Others', 'Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267808/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241493, 'Iron protein succinylate', 'Cinoxacin', 'Moderate', 'Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics.  Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc.  The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.  When coadministered with Suprep Bowel Prep (magnesium/potassium/sodium sulfates), the manufacturer recommends administering fluoroquinolone antibiotics at least 2 hours before and not less than 6 hours after Suprep Bowel Prep to avoid chelation with magnesium.  Please consult individual product labeling for specific recommendations.', 'Absorption', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267811/', '', 'Enoxacin, Lomefloxacin, Grepafloxacin', 'Iron sucrose, Cyanocobalamin, Folic acid', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241494, 'Cinoxacin', 'Magaldrate', 'Moderate', 'Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics.  Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc.  The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.  When coadministered with Suprep Bowel Prep (magnesium/potassium/sodium sulfates), the manufacturer recommends administering fluoroquinolone antibiotics at least 2 hours before and not less than 6 hours after Suprep Bowel Prep to avoid chelation with magnesium.  Please consult individual product labeling for specific recommendations.', 'Absorption', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267815/', '', 'Enoxacin, Lomefloxacin, Grepafloxacin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241495, 'Cinoxacin', 'Magnesium glycinate', 'Moderate', 'Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics.  Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc.  The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.  When coadministered with Suprep Bowel Prep (magnesium/potassium/sodium sulfates), the manufacturer recommends administering fluoroquinolone antibiotics at least 2 hours before and not less than 6 hours after Suprep Bowel Prep to avoid chelation with magnesium.  Please consult individual product labeling for specific recommendations.', 'Absorption', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267818/', '', 'Enoxacin, Lomefloxacin, Grepafloxacin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241496, 'Cinoxacin', 'Melphalan flufenamide', 'Minor', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.', 'DDInter', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.  In six patients with newly diagnosed hematologic malignancy, treatment with various antineoplastic agents (cyclophosphamide, cytarabine, daunorubicin, doxorubicin, mitoxantrone, prednisolone, vincristine) decreased the mean peak serum concentration (Cmax) and area under the concentration-time curve (AUC 0 to 4 hours) of ciprofloxacin by approximately 46% each.  Data are not available for other quinolone antibiotics.', 'Absorption', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267822/', '', 'Bendamustine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241497, 'Cinoxacin', 'Oxtriphylline', 'Moderate', 'Some fluoroquinolones have been shown to decrease the hepatic metabolism of theophyllines.  The mechanism is inhibition of CYP450 1A2 hepatic metabolism.', 'DDInter', 'Interpatient variability of this effect makes it prudent to monitor patients who may not tolerate a small increase in theophylline levels.  Levofloxacin, sparfloxacin, and lomefloxacin have been reported to cause minor or no changes in theophylline levels and may be considered as alternatives.  Patients should be advised to report any signs of theophylline toxicity including nausea, vomiting, diarrhea, headache, restlessness, insomnia, seizures, or irregular heartbeat to their physicians.', 'Metabolism', 'Interpatient variability of this effect makes it prudent to monitor patients who may not tolerate a small increase in theophylline levels.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267829/', '', 'Gatifloxacin, Levofloxacin, Nalidixic acid, Gemifloxacin, Lomefloxacin, Moxifloxacin, Trovafloxacin, Delafloxacin, Sparfloxacin', 'Omalizumab, Tezepelumab, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241498, 'Cinoxacin', 'Phenylbutazone', 'Moderate', 'Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use.  The interaction has been reported most often with enoxacin.  It may occur with other fluoroquinolones as well, but is poorly documented.  The exact mechanism of interaction is unknown.  Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect.  Patients with a history of seizures may be at greater risk.', 'DDInter', 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267830/', '', 'Enoxacin, Lomefloxacin, Grepafloxacin', 'Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241499, 'Cinoxacin', 'Plicamycin', 'Minor', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.', 'DDInter', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.  In six patients with newly diagnosed hematologic malignancy, treatment with various antineoplastic agents (cyclophosphamide, cytarabine, daunorubicin, doxorubicin, mitoxantrone, prednisolone, vincristine) decreased the mean peak serum concentration (Cmax) and area under the concentration-time curve (AUC 0 to 4 hours) of ciprofloxacin by approximately 46% each.  Data are not available for other quinolone antibiotics.', 'Absorption', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267832/', '', 'Ixabepilone, Valrubicin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (241500, 'Cinoxacin', 'Rofecoxib', 'Moderate', 'Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use.  The interaction has been reported most often with enoxacin.  It may occur with other fluoroquinolones as well, but is poorly documented.  The exact mechanism of interaction is unknown.  Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect.  Patients with a history of seizures may be at greater risk.', 'DDInter', 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/267833/', '', 'Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole', '', 1767369485);
